İleri Evre Testis Tümörlerinin Tedavisi

Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: Renal, penile, and testicular tumours. European Urology, 70(1), 93–105. https://doi.org/10.1016/j.eururo.2016.02.029

Verrill, C., Yilmaz, A., Srigley, J. R., Amin, M. B., Compérat, E., Egevad, L., et al. (2017). Reporting and staging of testicular germ cell tumors: The International Society of Urological Pathology (ISUP) testicular cancer consultation conference recommendations. The American Journal of Surgical Pathology, 41(6), 22–32. https://doi.org/10.1097/PAS.0000000000000842

Tickoo, S. K., Hutchinson, B., Bacik, J., Mazumdar, M., Motzer, R. J., Bajorin, D. F., et al. (2002). Testicular seminoma: A clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. International Journal of Surgical Pathology, 10(1), 23–32. https://doi.org/10.1177/106689690201000104

Gholam, D., Fizazi, K., Terrier-Lacombe, M., Jan, P., Culine, S., & Theodore, C. (2003). Advanced seminoma—Treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: A single-institution experience in 145 patients. Cancer, 98(4), 745–752. https://doi.org/10.1002/cncr.11564

Mead, G. M., Stenning, S. P., Cook, P., Fossa, S. D., Horwich, A., Kaye, S. B., et al. (1997). International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. Journal of Clinical Oncology, 15(2), 594–603. https://doi.org/10.1200/JCO.1997.15.2.594

DeVita, V. T., Rosenberg, S. A., & Lawrence, T. S. (2022). DeVita, Hellman, and Rosenberg’s Cancer. Lippincott Williams & Wilkins.

Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., et al. (2019). Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 17(12), 1529–1554. https://doi.org/10.6004/jnccn.2019.0059

Motzer, R. J., Nichols, C. J., Margolin, K. A., Bacik, J., Richardson, P. G., Vogelzang, N. J., et al. (2007). Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Journal of Clinical Oncology, 25(3), 247–256. https://doi.org/10.1200/JCO.2006.06.6491

Horwich, A., Sleijfer, D. T., Fosså, S. D., Kaye, S. B., Oliver, R. T., Cullen, M. H., et al. (1997). Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. Journal of Clinical Oncology, 15(5), 1844–1852. https://doi.org/10.1200/JCO.1997.15.5.1844

Morris, M. J., & Bosl, G. J. (2000). Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. The Journal of Urology, 163(3), 796–801. https://doi.org/10.1016/S0022-5347(05)67814-8

Fizazi, K., Pagliaro, L., Laplanche, A., Fléchon, A., Mardiak, J., Geoffrois, L., et al. (2014). Personalized chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): A phase 3, multicentre, randomised trial. The Lancet Oncology, 15(13), 1442–1450. https://doi.org/10.1016/S1470-2045(14)70490-5

National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Testicular Cancer, Version 2.2024 — October 29, 2024. Retrieved from https://www.nccn.org

Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., et al. (2005). Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of Clinical Oncology, 23(27), 6549–6555. https://doi.org/10.1200/JCO.2005.06.105

Broun, E. R., Nichols, C. R., Gize, G., Cornetta, K., Hromas, R. A., Schacht, B., et al. (1997). Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer, 79(8), 1605–1610. https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1605::AID-CNCR8>3.0.CO;2-Q

Pico, J. L., Rosti, G., Kramar, A., Wandt, H., Koza, V., Salvioni, R., et al. (2005). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Annals of Oncology, 16(7), 1152–1159. https://doi.org/10.1093/annonc/mdi219

Lorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., et al. (2011). Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: Evidence from a large international database. Journal of Clinical Oncology, 29(16), 2178–2184. https://doi.org/10.1200/JCO.2010.33.0644

DeVita, V. T., Hellman, S., & Rosenberg, S. A. (Eds.). (2023). DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology (12th ed.). Wolters Kluwer.

Necchi, A., Bratslavsky, G., Corona, R. J., Chung, J. H., Millis, S. Z., Elvin, J. A., et al. (2020). Genomic characterization of testicular germ cell tumors relapsing after chemotherapy. European Urology Focus, 6(1), 122–130. https://doi.org/10.1016/j.euf.2019.04.006